INOVIQ Ltd (FRA:EGQ0)

Germany · Delayed Price · Currency is EUR

0.0860

+0.0040 (4.88%)

Last updated: Aug 27, 2026, 8:06 AM CET

-58.65% (1Y)

Market Cap	14.29M -42.5%
Revenue (ttm)	1.58M +17.4%
Net Income	-4.54M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0860
Previous Close	0.0820
Day's Range	0.0860 - 0.0860
52-Week Range	0.0820 - 0.3140
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can... [Read more]

Industry Gold And Silver Ores

Founded 2016

Employees 15

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol EGQ0

Financial Performance

In fiscal year 2026, INOVIQ's revenue was 2.61 million, an increase of 44.01% compared to the previous year's 1.82 million. Losses were -7.51 million, 8.26% more than in 2025.

Financial numbers in AUD Financial Statements